Skip to main content

Advertisement

SpringerLink
Log in

Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

We conducted this retrospective study to evaluate the effectiveness of giving oral anti-cancer drugs for 2 years as postoperative adjuvant chemotherapy to gastric cancer patients.

Methods

The subjects were 76 patients with stage II and III gastric cancer, who underwent curative surgery between 1989 and 2008. We divided the 20 years chronologically into the UFT term (1989–2003) and the S-1 term (2004–2008). The patients from each term were then divided into three groups according to the length of drug administration; namely, the surgery alone group, the 1-year group, and the 2-year group.

Results

The survival time of the 2-year group was better than that of the surgery alone group, not only in the UFT term, but also in the S-1 term (P = 0.0224). Longer relapse-free survival was evident in the S-1 term, especially for the 2-year group (P = 0.0110). A multivariate analysis showed both the stage of the cancer and 2 years of postoperative adjuvant chemotherapy to be independent factors predictive of prolonged survival (P = 0.0040 and P = 0.0022, respectively).

Conclusions

The 2-year administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy might improve the outcome of stage II, III gastric cancer patients. Randomized control trials are warranted to prove the effectiveness of this 2-year regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer. 1992;65:413–6.

    Article  PubMed  CAS  Google Scholar 

  2. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354:273–7.

    Article  PubMed  CAS  Google Scholar 

  3. Macdonald J, Smalley SR, Benedetti J, Hundahl SA, Norman C, Estes NC, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  PubMed  CAS  Google Scholar 

  4. Costanzo FD, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer. 2008;100:388–98.

    Article  Google Scholar 

  5. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468–76.

    Article  PubMed  CAS  Google Scholar 

  6. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, ACTS-GC Group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2008;357:1810–20.

    Article  Google Scholar 

  7. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer : meta-analysis of randomized trials. J clin oncology. 1993;11:1441–7.

    CAS  Google Scholar 

  8. Pignon JP, Ducreux M. P Rougier. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J clin oncol. 1994;12:877–8.

    PubMed  CAS  Google Scholar 

  9. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: A study of the GISCAD. Ann Oncol. 2000;11:837–43.

    Article  PubMed  CAS  Google Scholar 

  10. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009;14:85–9.

    Article  PubMed  CAS  Google Scholar 

  11. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.

    Article  PubMed  CAS  Google Scholar 

  12. Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: a comprehensive review. Gastric Cancer. 2001;4:175–84.

    Article  PubMed  CAS  Google Scholar 

  13. Kodama Y, Kano T, Tamada R, Kumashiro R, Okamura T, Inokuchi K. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach. Surg Today. 1982;12:244–8.

    CAS  Google Scholar 

  14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1998;1:10–24.

  15. Ringborg U. Adjuvant chemotherapy—a discussion of some basic principles. Acta Oncol. 1991;30:251–3.

    Article  PubMed  CAS  Google Scholar 

  16. Tannock I. Adjuvant chemotherapy—basic science. The basic science of oncology. 2004. p. 356–7.

  17. Epstein RJ. Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res. 2005;11:5337–41.

    Article  PubMed  CAS  Google Scholar 

  18. Hanaue H, Kurosawa T, Kitano Y, Miyakawa S, Nemoto A, et al. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Cancer. 1987;59:1571–6.

    Article  PubMed  CAS  Google Scholar 

  19. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol. 1997;40:233–8.

    Article  PubMed  CAS  Google Scholar 

  20. Kaibara N, Soejima K, Nakamura T, Inokuchi K. Postoperative long term cancer chemotherapy for advanced gastric cancer. Surg Today. 1976;6:54–9.

    CAS  Google Scholar 

  21. Okudaira Y, Sugimachi K, Inokuchi K, Kai H, Kuwano H, Matsuura H. Postoperative long term immunochemotherapy for esophageal carcinoma—5 year survival. Surg Today. 1982;12:249–56.

    CAS  Google Scholar 

  22. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6:2–8.

    Article  PubMed  Google Scholar 

  23. Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. 3rd edn. Japan: Japanese Gastric Cancer Association; 2010. p. 26–27 (in Japanese).

  24. Tanaka F. UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surg Today. 2007;37:923–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Toshiro Okuyama and his co-authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Fukuoka City Hospital, 13-1 Yoshizuka-honmachi, Hakata-ku, Fukuoka, 812-0046, Japan

    Toshiro Okuyama, Daisuke Korenaga, Ai Edagawa, Shinji Itoh, Hirofumi Kawanaka, Yasuharu Ikeda, Masahiro Tateishi & Kenji Takenaka

  2. Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Eiji Oki, Yoshihiro Kakeji, Shunichi Tsujitani & Yoshihiko Maehara

Authors
  1. Toshiro Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Korenaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ai Edagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinji Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiji Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirofumi Kawanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuharu Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshihiro Kakeji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shunichi Tsujitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kenji Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshihiko Maehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiro Okuyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuyama, T., Korenaga, D., Edagawa, A. et al. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today 42, 734–740 (2012). https://doi.org/10.1007/s00595-012-0129-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-012-0129-5

Keywords

Search

Navigation